Molecular targeted therapy heralded a new era for the treatment of patients with oncogene-
driven advanced-stage non–small-cell lung cancer (NSCLC). Molecular testing at the time of …

The established dogma in oncology for managing recurrent or refractory disease dictates
that therapy is changed at disease progression, because the cancer is assumed to have …

Background The EGFR T790M mutation is the most common mechanism of drug resistance
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …

A new class of EGFR PROTACs based on pomalidomide was developed, synthesised, and
tested for their cytotoxic activity against a panel of human cancer cells. Compounds 15–21 …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

Abstract Background The Japan Guidelines of Lung Cancer Therapy recommend epidermal
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …

Objective Previous studies have indicated that EGFR exon 19 deletions in non-small cell
lung cancer (NSCLC) are associated with better outcomes to tyrosine kinase inhibitors …

Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR)
gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for …

Purpose Preclinical studies demonstrated anti-tumor efficacy of the combination of the
histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in non-small cell lung cancer …